Skip to main content
. 2006 Apr 6;116(5):1410–1424. doi: 10.1172/JCI27607

Figure 6. HSJ1b, cystamine, and cysteamine regulate BDNF levels in HD.

Figure 6

(A) BDNF release was decreased (ANOVA, F 3,33 = 17.45; P < 0.0001) in 109Q/109Q cells compared with control cells (post-hoc Fisher’s test, P < 0.0001). This decrease was rescued when cells were transfected with HSJ1b (post-hoc Fisher’s test, P < 0.0001) or treated with 100 μM cystamine for 30 minutes (post-hoc Fisher’s test, P = 0.001). (B) Data (ANOVA, F 2,29 = 3.63; P = 0.0392) revealed a statistically significant increase in the amount of BDNF in the brains of mice treated with cystamine (post-hoc Fisher’s test, P = 0.015) or with cysteamine (post-hoc Fisher’s test, P = 0.04) compared with controls. (C) Data (ANOVA, F 3,49 =11.66; P < 0.0001) revealed a statistically significant increase in the amount of BDNF in the brains of mice treated with cysteamine (post-hoc Fisher’s test, P < 0.001). (D) Cysteamine increased BDNF levels in the striatum of the different genotypes (ANOVA, F 5,14 = 9.20; P < 0.0004): wild-type animals (post-hoc Fisher’s test, P = 0.002); bdnf+/+httm mice (R6/1mice; post-hoc Fisher’s test, P = 0.009); and bdnf+/–httm mice (post-hoc Fisher’s test, P = 0.024). *P < 0.05, **P < 0.01, and #P < 0.001.